All News
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE
Links:
Dr. John Cush RheumNow ( View Tweet)
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/yZqHEg73bn https://t.co/CzVH62LEgL
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5
Dr. John Cush RheumNow ( View Tweet)
The key data for treating clinically suspect arthralgias (CSA):
TREAT-EARLIER (MTX)
ARIAA, APIPPRA (abatacept)
but what we need to do going forward:
stratify pts better for studies
predict individual risk better, to weight up risk-benefit of intervention
#EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
David Liew drdavidliew ( View Tweet)
Key arguments for CSA skeptics:
- definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is
- we still struggle to prevent RA
- it’s easy to go down a therapeutic slippery slope, and hard to track back
- labels are hard to remove
#EULAR2023 @RheumNow https://t.co/4adop3IR8g
David Liew drdavidliew ( View Tweet)
Presenting work to improve referrals from primary care, reducing delays in diagnosis in rheumatic conditions. Sharing the set up of Rheumatology Academy and Collaborative Network (RheumACaN) and the impact it is making @RBNHSFT @NASSexercise @RheumatologyUK @RheumNow #EULAR2023 https://t.co/v0BBRiFtEy
Dr. Antoni Chan synovialjoints ( View Tweet)
Check out RheumNow's #EULAR23 coverage!
https://t.co/rGBWF0lx4g https://t.co/6SEon6poi4
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular 2023 Daily Recap Series https://t.co/ScW9jWvzl9
Dr. John Cush RheumNow ( View Tweet)
So Annette van der Helm-van Mil makes some clear arguments about why CSA is real. But Filip Van den Bosch gives his disclosure: the clinical rheumatologist’s inherent skepticism of ‘early disease’
#EULAR2023 @RheumNow https://t.co/GbaBhQE5AB
David Liew drdavidliew ( View Tweet)
ILD in RA and PsA
@AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD.
ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N
Links:
Dr. John Cush RheumNow ( View Tweet)
Using app for self-management in clinical care. There is a need to have continued engagement both patients and clinicians, constantly evolve the product, adapt to the changing needs of patients eg.pre and post pandemic, #WIIFM? @AurelieRheumo @ProfYelizPrior #EULAR2023 @RheumNow https://t.co/5RKog9EMsV
Dr. Antoni Chan synovialjoints ( View Tweet)
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm ( @AurelieRheumo )discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/Z39ibke3JD https://t.co/YvWbNz9tFH
Links:
Dr. John Cush RheumNow ( View Tweet)
The #EULAR2023 wall is growing..@RheumNow https://t.co/tpJSp5Yc9X
Dr. Antoni Chan synovialjoints ( View Tweet)
Very interesting.
Overweight fibromyalgia pts had some sustained benefit of their fibro on a very low calorie ketogenic diet (8 weeks ketogenic, 12 weeks carb reintroduce)
Pain improvements matched weight loss. Many questions, I want to see more!
POS1339 #EULAR2023 @RheumNow https://t.co/3rIPmSVUwj
David Liew drdavidliew ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
✅Benefit of adding #HydroxyChloroquine #HCQ in refractory obstetric #APS
#EULAR2023 poster https://t.co/dgGY496dbh
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Clinically suspect arthralgia-what is needed are predictors that enrich WHO will develop RA. Otherwise in 85% of Pts your (sham) Rx will work. If we need to reset the immune response- early makes sense but many will NOT have #RA over the next few yrs. @RheumNow #EULAR2023 https://t.co/vDv6cHqFUn
Janet Pope Janetbirdope ( View Tweet)
#EULAR2023 #OP0290 Heterogeneity in #SLE is not only disease features but think of ANCESTRY. Data from BILAG-BR registry showed worse outcomes in people of Black and South Asian treated with either Rituximab or Belimumab (adjusted for deprivation index) @RheumNow https://t.co/bcdu9RIFSx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Predictors of first hospitalizations due to disease activity and infections in #lupus 1341 pts from multicenter latin american cohort. 33% with atleast one hospitalization, and 3/4th due to disease activity.
@rheumnow #EULAR2023 abt#POS0169 https://t.co/vbJU4220is
Bella Mehta bella_mehta ( View Tweet)
